Search PubMedSearch

PubMed · 7801012

[Interventional bronchoscopy].

Abstract

The field of bronchoscopy has considerably expanded in recent years. The rigid and flexible bronchoscope are both used for diagnostic and increasingly for therapeutic procedures; for the therapeutic procedures the term 'interventional bronchoscopy' has been coined. Apart from the more traditional indications for interventional bronchoscopies, such as aspiration of secretions and removal of foreign bodies, the treatment of inoperable stenoses of the central airways--benign or malignant--has moved to the center stage of interventional endoscopies. This review focuses on the technique and indication of the following procedures: bronchial toilette, foreign body removal, dilatation, diathermy, cryotherapy, photodynamic therapy, laser resection, brachytherapy and the insertion of stents (endoprostheses).

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C T Bolliger. 1994-12-06. [Interventional bronchoscopy].. https://pubmed.ncbi.nlm.nih.gov/7801012/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

[Respiratory insufficiency caused by a vocal cord polyp. An accidental finding during respiratory function tests].

We present a case in which a 58-year-old woman was admitted for spirometry due to progressive dyspnoea. She had a history of chronic obstructive pulmonary disease treated for more than 20 years. The flow-volume loop indicated an upper airway obstruction. An otolaryngologic examination revealed a vocal cord polyp. It was excised and the patient's dyspnoea was relieved. The following spirometry indicated that the upper airway obstruction had been removed. The aim of this case report is to demonstrate that the flow-volume loop is a useful method in diagnosing and quantifying upper airway obstructions.

Airway Obstruction

Synthetic and structure/activity studies on acid-substituted 2-arylphenols: discovery of 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5- hydroxyphenoxy]-propoxy]phenoxy]benzoic acid, a high-affinity leukotriene B4 receptor antagonist.

Structural derivatives of LY255283 have been studied as receptor antagonists of leukotriene B4. Substitution of the 2-hydroxyacetophenone subunit of 1 (LY255283) with a 2-arylphenol group provided entry into several new series that feature various mono- and diacidic core functionality. These new analogues, the subject of a broad structure-activity investigation, displayed significantly increased in vitro and in vivo activity as receptor antagonists of LTB4. A series of diaryl ether carboxylic acids demonstrated especially interesting activity and led to the discovery of compound 43b, 2-[2-propyl-3-[3-[2-ethyl-4-(4- fluorophenyl)-5-hydroxyphenoxy]-propoxy]phenoxy]benzoic acid (LY293111), a 2-arylphenol-substituted diaryl ether carboxylic acid which displayed potent binding to human neutrophils (IC50 = 17 +/- 4.6 nM) and guinea pig lung membranes (IC50 = 6.6 +/- 0.71 nM), inhibition of LTB4-induced expression of the CD11b/CD18 receptor on human neutrophils (IC50 = 3.3 +/- 0.81 nM), and inhibition of LTB4-induced contraction of guinea pig lung parenchyma (pKB = 8.7 +/- 0.16). In vivo, 43b demonstrated potent activity in inhibiting LTB4-induced airway obstruction in the guinea pig when dosed by the oral (ED50 = 0.40 mg/kg) or intravenous (ED50 = 0.014 mg/kg) routes. A specific LTB4 receptor antagonist, 43b had little effect on inhibiting contractions of guinea pig lung parenchyma induced by leukotriene D4 (LTD4), histamine, carbachol, or U46619. Compound 43b has been chosen as a clinical candidate and is currently in phase I studies for a variety of inflammatory diseases.

Airway Obstruction